Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GREM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GREM1 ECD-Fc / His-tagged Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native disulfide-linked dimeric conformation. |
View GREM1 Products |
| Gene Delivery | GREM1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and functional reporter assays. |
View GREM1 Products |
| Benchmark Ab | Anti-GREM1 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View GREM1 Products |
| Validator | GREM1 siRNA Set For target knockdown and specificity validation in cell-based assays. |
View GREM1 Products |
| Related Target A | BMP4 Primary functional partner; GREM1 acts as a high-affinity antagonist to BMP4 signaling. |
View BMP4 Products |
| Related Target B | GREM2 Closest family homolog; essential for counter-screening to ensure candidate specificity. |
View GREM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving native homodimeric structure for functional BMP blocking assays | HEK293 expression system ensures correct disulfide bonding and native glycosylation patterns |
| Cross-species reactivity validation (Human vs. Mouse/Cyno) | Sequence-verified Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Off-target screening against highly homologous family members | Recombinant GREM2 and other BMP antagonists available for comprehensive selectivity profiling |
| Lack of controls for blocking validation | Clinical-grade benchmark biosimilar antibodies included in the catalog |
Live GREM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GREM1 therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine modulation to microenvironment-targeted monoclonal antibodies. As first-generation therapies for fibrotic diseases and stroma-rich tumors reach the clinic, the next wave of R&0 is targeting the dual role of GREM1 in suppressing Bone Morphogenetic Protein (BMP) signaling and activating VEGFR2-mediated angiogenesis.
GREM1 is highly overexpressed in cancer-associated fibroblasts (CAFs) within the tumor microenvironment of colorectal, pancreatic, and breast cancers, as well as in myofibroblasts during idiopathic pulmonary fibrosis (IPF). Consequently, drug discovery efforts are heavily focused on neutralizing antibodies that can restore homeostatic BMP signaling or block the non-BMP path of GREM1-VEGFR2 interaction without causing systemic toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Gremab, Elsiv, Academic Spin-offs | Idiopathic Pulmonary Fibrosis (IPF), Colorectal Cancer, Pancreatic Cancer | Functional Blocking Assay (Need sequence-verified, bioactive GREM1 to test BMP pathway restoration) |
| Bispecific Antibodies | Biotech Innovators | Stroma-rich Solid Tumors (e.g., CRC, PDAC) | Dual-Target Binding Assays (Need high-purity GREM1 paired with tumor-associated antigens like CEA or EGFR) |
| Small Molecule Inhibitors | Academic Lead Discovery | Fibrotic Disorders, Metastatic Cancers | High-Throughput Screening (HTS) & SPR Selectivity (Need recombinant GREM1 vs. GREM2 panels) |